The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210(Bcr-Abl) tyrosine kinase and induces apoptosis of K562 leukemic cells

Cancer Research

Volumn 60, Issue 12, 2000, Pages 3127-3131

  Dorsey, Jay F ^a,b   Jove, Richard ^a,b   Kraker, Alan J ^c   Wu, Jie ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; BCR ABL PROTEIN; PROTEIN TYROSINE KINASE; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL STRAIN HL 60; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELL NUCLEUS; ENZYME INHIBITORS; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; HL-60 CELLS; HUMANS; IMMUNOBLOTTING; INHIBITORY CONCENTRATION 50; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC; POLY(ADP-RIBOSE) POLYMERASES; PRECIPITIN TESTS; PYRIDONES; PYRIMIDINES; TIME FACTORS;

EID: 0034095603     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Clark, S. S., McLaughlin, J., Crist, W. M., Champlin, R., and Witte, O. N. Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science (Washington DC), 235: 85-88, 1987.
2. Daley, G., ven Etten, R., and Baltimore, D. Induction of chronic myelogenous leukemia in mice by the p210bcr/abl gene of the Philadelphia chromosome. Science (Washington DC), 247: 824-830, 1990.
3. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., and Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 2: 561-566, 1996.
4. McWhirter, J. R., and Wang, J. Y. J. Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein. Oncogene, 15: 1625-1634, 1997.
5. McWhirter, J. R., and Wang, J. Y. J. Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol.Cell. Biol., 11: 1553-1565, 1991.
6. Dou, Q. P., McGuire, T. F., Peng, Y., and An, B. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. J. Pharm. Exp. Ther., 289: 781-790, 1999.
7. Gambacorti-Passerini, C., Courtre, P. I., Mologni, L., Fanelli, M., Bertazzoli, C., Marchesi, E., Nicola, M. D., Biondi, A., Corneo, G. M., Belotti, D., Pogliani, E., and Lydon, N. B. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ ABL+ leukemic cells and induces apoptosis. Blood Cells Mol. Dis., 23: 380-394, 1997.
8. Anafi, M., Gazit, A., Zehavi, A., Ben-Neriah, Y., and Levitzki, A. Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood, 12: 3524-2529, 1993.
9. Kaur, G., Gazit, A., Levitzki, A., Stowe, E., Cooney, D. A., and Sausville, E. A. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anticancer Drugs, 5: 213-222, 1994.
10. Gu, H., Pratt, J. C., Burakoff, S. J., and Neel, B. J. Cloning of p97/Gab2, the major SHP2-binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation. Mol. Cell 2: 729-740, 1999.
11. Kraker, A. J., Hartl, B. G., Amar, A., M., Barvian, M. R., Showalter, H. D. H., and Moore, C. W. Biochemical and cellular effects of c-src selective pyhdo[2,3-d]pyrimidine tyrosine kinase inhibitors. Biochem. Pharmacol., in press, 2000.
12. Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., and Connelly, P. A. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. J. Biol. Chem., 277: 695-701, 1996.
13. Cunnick, J. M., Dorsey, J. F., Standley, T., Turkson, J., Kraker, A. J., Fry, D. W., Jove, R., and Wu, J. Role of tyrosine kinase activity of epidermal growth factor receptor in the lysophosphatidic acid-stimulated MAP kinase pathway. J. Biol. Chem., 273, 14468-14475, 1998.
14. Freshney, R. I. Culture of Animal Cells, a Manual of Basic Technique, Ed. 2, pp. 245-256. New York: Wiley-Liss, 1987.
15. Ten Hoeve, J., Arlinghaus, R. A., Guo, J. Q., Heisterkamp, N., and Groffen, J. Tyrosine phosphorylation of CrkL in Philadelphia+ leukemia. Blood, 84: 1731-1736, 1994.
16. Uemura, N., Salgia, R., Li, J-L., Saltier, M., and Griffin, J. D. The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins. Leukemia, 11: 376-385, 1997.
17. Foulkes, J. G., Chow, M., Gorka, C., Frackelton, A. R., Jr., and Baltimore, D. Purification and characterization of a protein-tyrosine kinase encoded by the Abelson murine leukemia virus. J. Biol. Chem., 260; 8070-8077, 1985.
18. Wang, J. Y. J., and Baltimore, D. Localization of tyrosine kinase-coding region in v-abl oncogene by the expression of v-abl-encoded proteins in bacteria. J, Biol. Chem., 260: 64-71, 1985.
19. Levitzki, A., and Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science (Washington DC), 267: 1782-1788, 1995.
20. Chaturvedi, P., Reddy, M. V. R., and Reddy, E. P. Src kinases and not JAKs activate STATs during IL-3 induced myeloid cell proliferation. Oncogene, 16: 1749-1758, 1998.